Carlsmed Reports Strong Q4 & Full-Year 2025 Revenue Growth, Expanding Margins, and Positive 2026 Outlook

summarizeSummary

Carlsmed announced robust Q4 and full-year 2025 financial results, featuring significant revenue growth, improved gross margins, and an optimistic revenue outlook for 2026.

check_boxKey Events

• Strong Revenue Growth

  Reported Q4 2025 revenue of $15.2 million, a 61.2% increase year-over-year, and full-year 2025 revenue of $50.5 million, an 86% increase over 2024.

• Gross Margin Expansion

  Achieved a gross margin of 76.5% for Q4 2025, up from 74.7% in Q4 2024, and 75.3% for the full year 2025, up from 73.8% in 2024.

• Increased Net Loss Amidst Growth

  Net loss for Q4 2025 was ($8.6) million, compared to ($4.7) million in Q4 2024, and full-year net loss was ($29.6) million, up from ($24.3) million in 2024, reflecting investments in growth.

• Positive 2026 Revenue Guidance

  Provided a 2026 revenue outlook in the range of $70 to $75 million, representing approximately 44% growth at the midpoint over 2025.

auto_awesomeAnalysis

Carlsmed, Inc. delivered robust financial results for Q4 and full-year 2025, demonstrating significant top-line growth and operational efficiency. The company reported an 86% increase in full-year revenue to $50.5 million and a 61.2% rise in Q4 revenue to $15.2 million, alongside expanding gross margins. While net losses increased, this is typical for a high-growth medical technology company investing heavily in research, development, and sales. The positive 2026 revenue guidance, projecting 44% growth at the midpoint, indicates continued strong momentum. Additionally, recent product launches and positive clinical data underscore the company's innovation and market penetration in personalized spine surgery solutions.